Monozide (Fosinopril Sodium, Hydrochlorothiazide)

Fosinopril sodium, the active ingredient in Monozide, is an ACE inhibitor presented as an oral tablet for systemic use. It is combined with hydrochlorothiazide to treat hypertension and edema associated with high blood pressure in adult patients.

GNH USA supplies Monozide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monozide is indicated for conditions that involve elevated blood pressure or fluid retention, acting through combined ACE inhibition and diuretic mechanisms.

Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. Edema associated with hypertension: promotes diuresis to decrease excess fluid volume. Combined blood‑pressure control: provides dual action of ACE inhibition and thiazide diuresis for patients needing both effects.

Monozide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Persistent dry cough due to ACE inhibition. - Increased urinary frequency or volume. - Headache or mild fatigue.

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or airway. - Severe dehydration or electrolyte imbalance (e.g., low potassium). - Acute renal impairment or sudden rise in serum creatinine. - Marked hypotension leading to syncope.

Before initiating Monozide, clinicians should consider several safety measures.

Monitor renal function: check serum creatinine and eGFR periodically. Check electrolytes: especially potassium and sodium levels. Avoid use in pregnancy: classified as Category D due to fetal risk. Use caution in hepatic impairment: dose adjustment may be required. Adjust dose for elderly patients: start low and titrate slowly. Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Monozide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Aliskiren combined with ACE inhibitors (risk of renal dysfunction and hyperkalemia). - Potassium‑sparing diuretics or supplements (excess potassium accumulation). - NSAIDs (may blunt antihypertensive effect and impair renal function).

Moderate Interactions (Monitor Closely): - Lithium (increased lithium levels, risk of toxicity). - Beta‑blockers or other antihypertensives (additive blood‑pressure lowering, monitor for hypotension). - Antidiabetic agents (possible enhancement of hypoglycaemic effect).